Stock Research for CGEN


Featured Broker: Ally Invest

Get the due diligence for another stock.


CGEN Stock Chart & Research Data

The CGEN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CGEN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


CGEN Due diligence Resources & Stock Charts

The CGEN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CGEN Detailed Price Forecast - CNN Money CNN View CGEN Detailed Summary - Google Finance
Yahoo View CGEN Detailed Summary - Yahoo! Finance Zacks View CGEN Stock Research & Analysis -

Stock Analysis

TradeIdeas View CGEN Trends & Analysis - Trade-Ideas Barrons View CGEN Major Holders - Barrons
NASDAQ View CGEN Call Transcripts - NASDAQ Seeking View CGEN Breaking News & Analysis - Seeking Alpha
Spotlight View CGEN Annual Report - OTC Report View CGEN OTC Short Report -
TradeKing View CGEN Fundamentals - TradeKing Charts View CGEN SEC Filings - Bar Chart
WSJ View Historical Prices for CGEN - The WSJ Morningstar View Performance/Total Return for CGEN - Morningstar
MarketWatch View the Analyst Estimates for CGEN - MarketWatch CNBC View the Earnings History for CGEN - CNBC
StockMarketWatch View the CGEN Earnings - StockMarketWatch MacroAxis View CGEN Buy or Sell Recommendations - MacroAxis
Bullish View the CGEN Bullish Patterns - American Bulls Short Pains View CGEN Short Pain Metrics -

Social Media Mentions

StockTwits View CGEN Stock Mentions - StockTwits PennyStocks View CGEN Stock Mentions - PennyStockTweets
Twitter View CGEN Stock Mentions - Twitter Invest Hub View CGEN Investment Forum News - Investor Hub
Yahoo View CGEN Stock Mentions - Yahoo! Message Board Seeking Alpha View CGEN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for CGEN - Insider Cow View Insider Transactions for CGEN - Insider Cow
CNBC View CGEN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CGEN - OTC Markets
Yahoo View Insider Transactions for CGEN - Yahoo! Finance NASDAQ View Institutional Holdings for CGEN - NASDAQ

Stock Charts

FinViz View CGEN Stock Insight & Charts - StockCharts View CGEN Investment Charts -
BarChart View CGEN Stock Overview & Charts - BarChart Trading View View CGEN User Generated Charts - Trading View

Latest Financial News for CGEN

New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Biotherapeutics, ElectraMeccanica Vehicles, Compugen, and China HGS Real Estate — Consolidated Revenues, Company Growth, and Expectations for 2018
Posted on Friday November 23, 2018

NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

Compugen Announces Issuance of U.S. Patent for COM902, Its TIGIT Antibody Product Candidate for Cancer Immunotherapy
Posted on Tuesday November 13, 2018

HOLON, Israel, Nov. 13, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that a patent for COM902, the Company's TIGIT therapeutic antibody candidate, has been issued by the United States Patent and Trademark Office (USPTO) under the USPTO's Cancer Moonshot Pilot Program providing early examination of patent applications pertaining to cancer immunotherapy. Activating T cells results in stimulating the immune system, and therefore could be used for cancer immunotherapy treatment. This patent as well as other patents the Company is pursuing for COM902 are part of its global patent strategy covering its innovative immuno-oncology pipeline.

Compugen (CGEN) Reports Q3 Loss
Posted on Wednesday November 07, 2018

Compugen (CGEN) delivered earnings and revenue surprises of 58.33% and 0.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

Compugen: 3Q Earnings Snapshot
Posted on Wednesday November 07, 2018

The Holon, Israel-based company said it had a loss of 5 cents per share. The drug developer posted revenue of $7.8 million in the period. The company's shares closed at $3.08. A year ago, they were trading ...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.